Annexin A1 peptide protects human retinal neurons from high-glucose damage in lab models
A peptide derived from the body's own anti-inflammatory protein Annexin A1 protected retinal neurons from damage caused by high glucose in laboratory models of the human eye. The work, published in Biomedicine & Pharmacotherapy, points to a way of shielding nerve cells in diabetic retinopathy, a complication that affects more than 22% of people with diabetes worldwide.
Testing the peptide in human retinal models
The study was led by Rafael André da Silva of the University of Colorado Anschutz, with colleagues from the Federal University of São Paulo (UNIFESP), São Paulo State University (UNESP) and Colorado. The team examined Ac2-26, a short fragment of Annexin A1. Experiments used cultured retinal cells and three-dimensional retinal organoids, both derived from patients' stem cells. The organoids reproduce part of the cell diversity and layered structure of the human retina, and the researchers exposed them to conditions mimicking the high-glucose, inflammatory environment of diabetes.
Under these conditions, Ac2-26 lowered inflammation, limited oxidative stress and helped preserve mitochondrial function. Together, these effects prevented the death of neurons exposed to high glucose.
The proposed mechanism
According to the authors, the peptide binds to a cell receptor called FPR2. This interaction restrains two molecules, p38 and NOX4, which promote the production of free radicals. Excess free radicals drive oxidative stress and damage mitochondria, so dampening this pathway helps cells keep functioning and survive.
The study also highlighted Müller cells, a type of glial cell spanning the retina that supports and defends neurons. Under stress these cells can overreact in a process called gliosis, which amplifies inflammation and contributes to neuronal loss. In the organoids, Ac2-26 curbed this response and altered the inflammatory environment of the tissue.
Why neurons matter
In diabetic retinopathy, inflammation and oxidative stress cause retinal neurons to die early. As damage builds, the eye forms new, fragile blood vessels, which can rupture and bleed, worsening vision loss. Da Silva noted that existing therapies mainly target this later neovascularisation stage and often come too late to protect neurons, which do not regenerate.
Natalia Vergara, director of the Laboratory of Ocular Development and Translational Technologies at CellSight, Colorado Anschutz, said the findings support viewing the disease as more than a vascular condition, since neurons are harmed even in early stages. She suggested that therapies acting directly on neural tissue could complement present treatments.
The work builds on an earlier paper from the group of Cristiane Gil (UNIFESP) in Investigative Ophthalmology & Visual Science, which described Annexin A1's role in regulating inflammation and in changes to blood vessels and glial cells. The peptide had not previously been tested in organoids modelling diabetic retinopathy.
Limitations and next steps
All results come from cell cultures and organoids, which cannot capture the full complexity of a living eye, including blood flow, long-term disease progression and drug delivery. The source does not report any animal or human data for this peptide in diabetic retinopathy.
The researchers say the next stages will be studies in animal models and then in humans. Gil said the longer-term aim is to develop topical formulations applied at the first signs of retinopathy. Whether such a preparation can reach the retina at effective concentrations, and whether the protective effect holds in vivo, remain open questions.
For the field, the study offers a candidate neuroprotective pathway, centred on FPR2, p38 and NOX4, and shows the value of combining human organoid models with long-standing expertise in Annexin A1 biology.
Source: Anti-inflammatory peptide shows potential to prevent diabetes-related vision loss (Medical Xpress, 20 November 2026).
Image: AI-generated illustration.
Working on this topic? Find a journal for your research or join the discussion on Scholars Post.


